---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-294634"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2025-11-25T23:59:59+00:00"
generated_at: "2026-05-16T17:04:36.817418+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics raises $1.5M in registered direct offering priced at $0.335/share

## Summary
- Sold 4,477,614 shares at $0.335/share; gross proceeds ~$1.5M before fees.
- Concurrent private placement of 4,477,614 warrants at $0.335 exercise price; exercisable upon stockholder approval.
- H.C. Wainwright placement agent gets 7.0% cash fee, 1.0% management fee, and 313,433 placement agent warrants at $0.4188.
- Net proceeds for working capital and general corporate purposes.
- 30-day lock-up on equity issuances; one-year ban on Variable Rate Transactions.

## SEC filing metadata
- accession: 0001193125-25-294634
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2025-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000119312525294634/0001193125-25-294634-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000119312525294634/fblg-20251124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-294634
- JSON: https://secwatch.observer/filing/0001193125-25-294634.json
- Plain text: https://secwatch.observer/filing/0001193125-25-294634.txt

## Key facts
- Equity Issuances
  FibroBiologics, Inc. issued to purchase up to 313,433 shares of Common Stock of warrant to Placement Agent (H.C. Wainwright & Co., LLC) for issued as compensation; exercise price $0.4188 per share.
  - Security: warrant
  - Shares: to purchase up to 313,433 shares of Common Stock
  - Purchaser: Placement Agent (H.C. Wainwright & Co., LLC)
  - Consideration: issued as compensation; exercise price $0.4188 per share
  source text: Additionally, the Company will issue to the Placement Agent (or its designees) warrants to purchase 7.0% of the number of Shares of Common Stock sold in this the Registered Direct Offering (or warrants to purchase up to 313,433 shares of Common Stock), at an exercise price of $0.4188 per share (the “Placement Agent Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000119312525294634/0001193125-25-294634-index.htm
- Equity Issuances
  FibroBiologics, Inc. issued to purchase 4,477,614 shares of Common Stock of warrant to institutional investors (the Purchasers) for exercise price $0.335 per share; no additional consideration at issuance.
  - Security: warrant
  - Shares: to purchase 4,477,614 shares of Common Stock
  - Purchaser: institutional investors (the Purchasers)
  - Consideration: exercise price $0.335 per share; no additional consideration at issuance
  source text: 4,477,614 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”). The price of each Share in the Registered Direct Offering is $0.335 (the “Offering Price”). Additionally, pursuant to the Purchase Agreement, the Company will issue and sell to the Purchasers, in a concurrent private placement, warrants to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000119312525294634/0001193125-25-294634-index.htm
- Material Agreements
  FibroBiologics, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $1.5 million (effective 2025-11-24).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $1.5 million
  - Effective: 2025-11-24
  source text: On November 24, 2025, FibroBiologics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which (i) the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 4,477,614 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1958777/000119312525294634/0001193125-25-294634-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.